Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy.

BACKGROUND Hypertrophic cardiomyopathy (HCM), which is inherited as an autosomal dominant trait, is the most prevalent hereditary cardiac disease. Although there are several reports on the systematic screening of mutations in the disease-causing genes in European and American populations, only limited information is available for Asian populations, including Japanese. METHODS AND RESULTS Genetic screening of disease-associated mutations in 8 genes for sarcomeric proteins, MYH7, MYBPC3, MYL2, MYL3, TNNT2, TNNI3, TPM1, and ACTC, was performed by direct sequencing in 112 unrelated Japanese proband patients with familial HCM; 37 different mutations, including 13 novel ones in 5 genes, MYH7, MYBPC3, TNNT2, TNNI3, and TPM1, were identified in 49 (43.8%) patients. Among them, 3 carried compound heterozygous mutations in MYBPC3 or TNNT2. The frequency of patients carrying the MYBPC3, MYH7, and TNNT2 mutations were 19.6%, 10.7%, and 8.9%, respectively, and the most frequently affected genes in the northeastern and southwestern parts of Japan were MYBPC3 and MYH7, respectively. Several mutations were found in multiple unrelated proband patients, for which the geographic distribution suggested founder effects of the mutations. CONCLUSIONS This study demonstrated the frequency and distribution of mutations in a large cohort of familial HCM in Japan.

[1]  T. Arimura,et al.  Genetic screening and double mutation in Japanese patients with hypertrophic cardiomyopathy. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[2]  B. Maron.  Risk stratification and role of implantable defibrillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. , 2010, Circulation journal : official journal of the Japanese Circulation Society.

[3]  R. Porcher,et al.  Prevalence and spectrum of mutations in a cohort of 192 unrelated patients with hypertrophic cardiomyopathy. , 2010, European journal of medical genetics.

[4]  A. Kimura,et al.  Molecular basis of hereditary cardiomyopathy: abnormalities in calcium sensitivity, stretch response, stress response and beyond , 2010, Journal of Human Genetics.

[5]  Barry J Maron,et al.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.

[6]  H. Katus,et al.  The sarcomeric Z-disc: a nodal point in signalling and disease , 2006, Journal of Molecular Medicine.

[7]  Susana Santos,et al.  Hypertrophic cardiomyopathy in a Portuguese population: mutations in the myosin-binding protein C gene. , 2005, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology.

[8]  J. Seidman,et al.  Compound and double mutations in patients with hypertrophic cardiomyopathy: implications for genetic testing and counselling , 2005, Journal of Medical Genetics.

[9]  H. Mabuchi,et al.  Phenotypic differences between electrocardiographic and echocardiographic determination of hypertrophic cardiomyopathy in genetically affected subjects , 2005, Journal of internal medicine.

[10]  R. Dietz,et al.  Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy , 2005, Journal of Molecular Medicine.

[11]  Masahiko Hoshijima,et al.  Tcap gene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[12]  A. Tajik,et al.  Myosin binding protein C mutations and compound heterozygosity in hypertrophic cardiomyopathy. , 2004, Journal of the American College of Cardiology.

[13]  Erik G. Ellsworth,et al.  Prevalence and Spectrum of Thin Filament Mutations in an Outpatient Referral Population With Hypertrophic Cardiomyopathy , 2003, Circulation.

[14]  M. Komajda,et al.  Hypertrophic Cardiomyopathy: Distribution of Disease Genes, Spectrum of Mutations, and Implications for a Molecular Diagnosis Strategy , 2003, Circulation.

[15]  J. Mogensen,et al.  Comparison of fluorescent SSCP and denaturing HPLC analysis with direct sequencing for mutation screening in hypertrophic cardiomyopathy , 2003, Journal of medical genetics.

[16]  K. Hayashi,et al.  A novel missense mutation in the myosin binding protein-C gene is responsible for hypertrophic cardiomyopathy with left ventricular dysfunction and dilation in elderly patients. , 2003, Journal of the American College of Cardiology.

[17]  H. Vosberg,et al.  Low‐density DNA microarrays are versatile tools to screen for known mutations in hypertrophic cardiomyopathy , 2002, Human mutation.

[18]  J. Seidman,et al.  Homozygous Mutation in Cardiac Troponin T: Implications for Hypertrophic Cardiomyopathy , 2000, Circulation.

[19]  M. Yokota,et al.  Phenotypic Variation of Familial Hypertrophic Cardiomyopathy Caused by the Phe110→Ile Mutation in Cardiac Troponin T , 2000, Cardiology.

[20]  C. Tei,et al.  Novel cardiac β‐myosin heavy chain gene missense mutations (R869C and R870C) that cause familial hypertrophic cardiomyopathy , 2000 .

[21]  T. Imaizumi,et al.  Malalignment of the sarcomeric filaments in hypertrophic cardiomyopathy with cardiac myosin heavy chain gene mutation , 1999, Heart.

[22]  A. Kisanuki,et al.  Patients with familial hypertrophic cardiomyopathy caused by a Phe110Ile missense mutation in the cardiac troponin T gene have variable cardiac morphologies and a favorable prognosis. , 1998, Circulation.

[23]  H Niimura,et al.  Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. , 1998, The New England journal of medicine.

[24]  B Maisch,et al.  Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. , 1996, Circulation.

[25]  R. Matsuoka,et al.  Missense mutation of the beta-cardiac myosin heavy-chain gene in hypertrophic cardiomyopathy. , 1995, American journal of medical genetics.

[26]  T. Kishimoto,et al.  Novel missense mutation in α-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy , 1995 .

[27]  J. Seidman,et al.  Mutations in the genes for cardiac troponin T and alpha-tropomyosin in hypertrophic cardiomyopathy. , 1995, The New England journal of medicine.

[28]  J. Seidman,et al.  Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. , 1992, The New England journal of medicine.

[29]  J. Seidman,et al.  A molecular basis for familial hypertrophic cardiomyopathy: A β cardiac myosin heavy chain gene missense mutation , 1990, Cell.

[30]  V. Álvarez,et al.  [Mutations in sarcomeric genes MYH7, MYBPC3, TNNT2, TNNI3, and TPM1 in patients with hypertrophic cardiomyopathy]. , 2009, Revista espanola de cardiologia.

[31]  R. Dietz,et al.  Prevalence of cardiac beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy , 2005, Journal of Molecular Medicine.

[32]  Y. Zhen,et al.  Mutations profile in Chinese patients with hypertrophic cardiomyopathy. , 2005, Clinica chimica acta; international journal of clinical chemistry.

[33]  T. Hayashi,et al.  Molecular etiology of idiopathic cardiomyopathy in Asian populations. , 2001, Journal of cardiology.

[34]  C. Tei,et al.  Novel cardiac beta-myosin heavy chain gene missense mutations (R869C and R870C) that cause familial hypertrophic cardiomyopathy. , 2000, Human mutation.

[35]  T. Kishimoto,et al.  Novel missense mutation in alpha-tropomyosin gene found in Japanese patients with hypertrophic cardiomyopathy. , 1995, Journal of molecular and cellular cardiology.